Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Kalvista Pharmaceuticals Inc
(NQ:
KALV
)
9.090
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kalvista Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
Next >
KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema
October 04, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop
September 30, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharma: Q1 Earnings Insights
September 08, 2022
KalVista Pharma (NASDAQ:KALV) reported its Q1 earnings results on Thursday, September 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
September 08, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 23, 2022
Via
Benzinga
KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off
August 23, 2022
KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema...
Via
Benzinga
KalVista Pharmaceuticals Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema
August 23, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried
August 22, 2022
Shares hit their lowest point since November on the FDA's decision in HAE.
Via
Investor's Business Daily
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference
July 19, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Recap: KalVista Pharmaceuticals Q4 Earnings
July 07, 2022
KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q4 earnings results on Thursday, July 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
July 07, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program
July 05, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
June 23, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program
June 08, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare Conference
June 01, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces Changes to Board of Directors
May 27, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900
May 17, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference
April 11, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy
March 22, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals: Q3 Earnings Insights
March 10, 2022
KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q3 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here's what investors need to know about the...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...
Via
Talk Markets
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
February 03, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022
February 02, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.